Strategies to overcome interleukin-1-mediated immune suppression and resistance to immunotherapy in cancer

Abhishek Puthenveetil, Shweta Dubey, Ankita Garg

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review


Immunotherapy has brought about a radical change in the treatment landscape of cancer. However, only 20%–30% of patients with cancer show a durable clinical response to any of the available tumor immunotherapy approaches. Since tumor cells use a variety of pathways for their survival, resistance to immunotherapy in cancer is a multifactorial process. Interleukin-1 (IL-1) is one important cytokine that plays a crucial role in mediating resistance to immunotherapy. IL-1-mediated immunosuppression is characterized by multiple interlinked pathways including but not limited to metabolic rewiring and epigenetic modification of tumor cells, leading to acquired resistance to therapies. Therefore, novel combination therapies are essential to overcome drug resistance. This chapter details the role of IL-1 in cancer progression and how inhibiting IL-1 axes may help in maximizing the gains from cancer immunotherapy. Potential combination therapies that can be applied to overcome IL-1-mediated drug resistance are also discussed.

Original languageEnglish
Title of host publicationMultifaceted Role of IL-1 in Cancer and Inflammation
Number of pages27
ISBN (Electronic)9780128242735
ISBN (Print)9780323859677
StatePublished - 1 Jan 2023

Bibliographical note

Publisher Copyright:
© 2023 Elsevier Inc. All rights reserved.


  • IL-1 inflammation and blockade therapy
  • IL-1-mediated resistance
  • Immunotherapy
  • Strategies for therapeutic interventions


Dive into the research topics of 'Strategies to overcome interleukin-1-mediated immune suppression and resistance to immunotherapy in cancer'. Together they form a unique fingerprint.

Cite this